SOUTH SAN FRANCISCO, Calif., July 5, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medication oncology firm dedicated to the invention and improvement of focused therapeutics, as we speak introduced that the corporate plans to subject a pre-market press launch and conduct an investor webcast on Monday, July 8, 2024, at 8:00 a.m. EST to supply a medical information replace for the IDE397 Part 2 monotherapy growth dose in MTAP-deletion urothelial and non-small cell lung most cancers (NSCLC) sufferers. IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha (MAT2A) inhibitor in Part 2 medical trials for the remedy of methylthioadenosine phosphorylase (MTAP) deletion stable tumors.
The investor webcast presentation agenda to evaluation the IDE397 medical information replace of the Part 2 growth dose ends in MTAP-deletion urothelial and NSCLC sufferers would be the following:
- Market introduction: U.S. annual incidence in MTAP-deletion stable tumors
- IDE397 preclinical abstract in MTAP-deletion
- Affected person baseline traits
- Pharmacokinetics and pharmacodynamics
- Antagonistic occasion profile
- Medical efficacy in 18 evaluable MTAP-deletion urothelial and NSCLC sufferers by RECIST 1.1
- General Response Charge (%ORR) and Illness Management Charge (%DCR) evaluation
- Swimlane plot
- ctDNA molecular response evaluation
- Case stories and CT-scan photographs
The IDEAYA audio system will embody Yujiro S. Hata, Chief Govt Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer. The hyperlink to the investor webcast shall be out there on the Investor Relations Occasions part of the Firm’s web site at: https://ir.ideayabio.com/occasions. Registration is obtainable at https://ir.ideayabio.com/occasions or https://lifescievents.com/occasion/ideaya-2/ upfront of the occasion.
IDEAYA’s IDE397 investor webcast presentation, in addition to an up to date company presentation, which can incorporate the up to date IDE397 medical information, shall be out there on the corporate’s web site, at its Investor Relations portal (https://ir.ideayabio.com/) at roughly 8:00 am ET on Monday, July 8, 2024.
There may be an ongoing Part 2 growth of IDE397 monotherapy in MTAP-deletion stable tumors (NCT04794699), and an Amgen-sponsored Part 1/2 trial of IDE397 and Amgen’s investigational MTA-cooperative protein arginine methytranferase 5 inhibitor AMG 193 mixture in MTAP-deletion NSCLC (NCT05975073) for which the businesses intend to develop a joint publication technique in 2024. As well as, IDEAYA has initiated enrollment in a Part 1 medical trial evaluating the protection, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 together with Gilead’s Trop-2 directed anti-body conjugate Trodelvy (NCT04794699). IDEAYA can be advancing a number of preclinical stage MTAP-deletion packages to allow wholly-owned mixtures with IDE397, together with a program concentrating on a improvement candidate nomination within the second half of 2024.
About IDEAYA Biosciences
IDEAYA is a precision medication oncology firm dedicated to the invention and improvement of focused therapeutics for affected person populations chosen utilizing molecular diagnostics. IDEAYA’s strategy integrates capabilities in figuring out and validating translational biomarkers with drug discovery to pick out affected person populations probably to learn from its focused therapies. IDEAYA is making use of its analysis and drug discovery capabilities to artificial lethality – which represents an rising class of precision medication targets.
Ahead-Wanting Statements
This press launch accommodates forward-looking statements, together with, however not restricted to, statements associated to (i) the timing and content material of the IDE397 medical information replace press launch, investor webcast and investor shows, (ii) the timing for the event of a joint Amgen/IDEAYA publication technique for the Part 1/2 IDE397 and AMG 193 mixture, (iii) the timing of preclinical stage MTAP-deletion packages together with IDE397 and (iv) nomination of an IDE397 mixture improvement candidate within the second half of 2024. IDEAYA undertakes no obligation to replace or revise any forward-looking statements. Such forward-looking statements contain substantial dangers and uncertainties. For an extra description of the dangers and uncertainties that might trigger precise occasions and outcomes to vary from these expressed in these forward-looking statements, in addition to dangers referring to the enterprise of IDEAYA generally, see IDEAYA’s Annual Report on Type 10-Okay filed on February 20, 2024, Quarterly Report on Type 10-Q filed on Might 7, 2024 and any further present and periodic stories filed with the U.S. Securities and Change Fee.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
[email protected]
SOURCE IDEAYA Biosciences, Inc.
